# INTERVIEW: Evgen Pharma Plc Strong progress, New initiatives & Favourable results

- Link: https://www.directorstalkinterviews.com/interview-evgen-pharma-plc-strong-progress-new-initiatives-favourable-results/412730216
- Published: 2017-06-13T09:30:54+01:00
- Author: Giles Arbor

**Evgen Pharma Plc** (LON:EVG) CEO Dr Stephen Franklin talks to DirectorsTalk about
its final results for the year ended 31 March 2017. Stephen reminds us of who Evgen
Pharma are and what is in the development pipeline at the moment, talks us through
the main result highlights and explains when the current clinical trials report,
and what else can we expect in terms of news flow between now and then.

 

Evgen Pharma Plc is a clinical stage drug development company whose lead programmes
are in breast cancer and subarachnoid haemorrhage, a type of stroke.  It is also
carrying out preclinical work in multiple sclerosis and has a clinical interest 
in prostate cancer.  The Company’s core technology is Sulforadex®, a method for 
synthesising and stabilising the naturally occurring compound sulforaphane and novel
proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented
composition of synthetic sulforaphane and alpha-cyclodextrin.  The company commenced
operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire
and its registered office is at the Liverpool Science Park, Liverpool. 

Share on: